Wire · opportunities
Argentine biotech developing first treatment of haemolytic uraemic syndrome
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 October 2026 · Fusion42 review
Argentine biotech company Inmunova is developing INM004, potentially the world's first specific treatment for haemolytic uraemic syndrome (HUS), a rare disease mainly affecting children caused by Shiga toxin-producing Escherichia coli bacteria. The drug is currently in Phase 3 clinical trials involving 220 children across Argentina and Europe, targeting a disease with no specific treatment and high incidence in Argentina.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You are facing a new market gap in treating haemolytic uraemic syndrome as Inmunova's drug nears approval. Use this window to prepare partnerships or expand diagnostic and care tools around this rare but critical paediatric condition.
◆ Coverage
1 source · 3 Oct 2026
◆ Related on Wire
◆ Topics